Radcliffe Capital Management’s Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 CLDI.WS Stock Holding History

Radcliffe Capital Management’s Portfolio CLDI.WS Stock Details CLDI.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-264,799	Closed	-$31.6K	–	500
2023 Q2	$31.6K	Hold	264,799	–	–	﹤0.01%	281
2023 Q1	$13K	Hold	264,799	–	–	﹤0.01%	497
2022 Q4	$2.69M	Hold	264,799	–	–	0.09%	373
2022 Q3	$2.61M	Buy	264,799 +64,800	+32%	+$3.9K	0.06%	517
2022 Q2	$1.99M	Hold	199,999	–	–	0.05%	682
2022 Q1	$1.98M	Hold	199,999	–	–	0.05%	672
2021 Q4	$1.96M	Buy	+199,999	New	+$113K	0.05%	576

Other funds holding CLDI.WS

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return

SCM

Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return

Arena Investors Purchase, New York $12.5M AUM 0.27% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

EFI

EHP Funds Inc Toronto, Canada $43.6M AUM 69.08% 1-Year Est. Return

ETH

Exos TFP Holdings New York $162M AUM 16.08% 1-Year Est. Return

Radcliffe Capital Management's CLDI.WS Position: Q3 2023 in Review

Radcliffe Capital Management sold out of Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 (CLDI.WS) in Q3 2023, closing a stake of 264,799 shares — an estimated $31.6K sold.

Radcliffe Capital Management first reported a position in CLDI.WS in Q4 2021 and held it in 7 quarters. The position peaked at $2.69M in Q4 2022. 21 funds tracked by Wall St. Rank hold CLDI.WS as of Q3 2023.

Radcliffe Capital Management reported no remaining Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 position as of Q3 2023 after selling out during the quarter.
Radcliffe Capital Management sold 264,799 Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 shares in Q3 2023, an estimated $31.6K.
Radcliffe Capital Management first reported a position in Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 in Q4 2021 and held it in 7 quarters.
Radcliffe Capital Management's Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 position peaked at $2.69M in Q4 2022.
21 funds tracked by Wall St. Rank held Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 as of Q3 2023.

Based on Radcliffe Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.